<FORM>
a. Incident cases                                                   b. Prevalent  cases
</FORM>
<TEXT>
Note: ‘Pharmerging’ is a group of 21 countries with less than US$ 30 000 GDP per capita and greater than US$ 1 billion in the growth of sales for prescription medicines between 2014 and 2019, as defined by the data source: China, Brazil, India, Russian Federation, Mexico, Turkey, Poland, Saudi Arabia, Indonesia, Egypt, Philippines, Pakistan, Viet Nam, Bangladesh, Argentina, Algeria, Colombia, South Africa, Chile, Nigeria, Kazakhstan. European Union Five includes France, Germany, Italy, Spain and the United Kingdom of Great Britain and Northern Ireland
</TEXT>
<SECTION_HEADER>
1.1.3 Stakeholder reactions and governments’ responses
</SECTION_HEADER>
<TEXT>
The growing expenditure and high prices of cancer medicines have attracted an extensive body of commentary from diverse stakeholders in recent years. Stakeholders at all levels – from patients and clinicians to governments – have expressed their concerns that such high prices would compromise the availability and affordability of these medicines to patients, as well as the sustainability of health systems.
</TEXT>
<TEXT>
For example, in 2011, the Lancet Oncology Commission on Global Cancer in cancer policy” and that “cancer profession and industry should take responsibility and not accept a substandard evidence base and an ethos of very small benefit at whatever cost; rather, we need delivery of fair prices and real value from new technologies” (28). In 2012, an article published in the New York Times highlighted that ignoring the cost of cancer treatment was “not tenable” (29). In 2013, a group of more than 100 experts in chronic myeloid leukaemia pointed to Stakeholders concerns adequate medicines
</TEXT>
<TEXT>
the fact that 11 of the 12 medicines approved by the United States Food & Drug Administration (US FDA) in 2012 for various cancer indications were priced above US$ 100 000 per year. The experts asserted that the prices of these medicines were too high, unsustainable, might compromise access of needy patients to highly effective therapy, and harmful to the sustainability of national health care systems (30). Similarly, in 2015, yet another group of cancer experts have petitioned for lower medicine prices (31).
</TEXT>
<TEXT>
Despite the chorus of concerns, existing regulatory and non-regulatory measures do not seem to have suitably resulted in outcomes that meet both policy and economic objectives, as well as public expectations. Stakeholders continue to voice their concerns about the lack of adequate access to both new and off-patent essential cancer medicines. Furthermore, the prices of cancer medicines continue to rise significantly, possibly disproportionally to the benefits conferred and to the extent that the financial sustainability of
</TEXT>
<UNSPECIFIED>
Source: Author’s  calculations based on  data from WHO    Global Health  Expenditure  Database  (27) and IQVIA  Institute for Human
         Data Science  (19)
4
</UNSPECIFIED>
<PAGE_BREAK>
